HALO (Halozyme Therapeutics) Total Stockholders Equity: $144 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HALO Halozyme Therapeutics Inc HALO
91 GF Score
Price $106.90
GF Value $98.18
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Halozyme Therapeutics Total Stockholders Equity?

Halozyme Therapeutics HALO -0.13% 91 Total Stockholders Equity is $144 Mil as of Jun. 2026. GuruFocus rates HALO with a GF Score™ of 91/100 and a GF Value™ of $98.18 (Fairly Valued). The stock has 5 warning signs investors should review.

Halozyme Therapeutics's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $144 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Halozyme Therapeutics's Book Value per Share for the quarter that ended in Jun. 2026 was $1.26. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Halozyme Therapeutics's Debt-to-Equity for the quarter that ended in Jun. 2026 was 14.95.

Halozyme Therapeutics  (NAS:HALO) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Halozyme Therapeutics's Book Value per Share for the quarter that ended in Jun. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(143.543-0)/114.042
=1.26

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Halozyme Therapeutics's Debt-to-Equity for the quarter that ended in Jun. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(208.97 + 1937.684) / 143.543
=14.95

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Halozyme Therapeutics Total Stockholders Equity Related Terms

Halozyme Therapeutics Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Halozyme Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Halozyme Therapeutics Total Stockholders Equity Chart

Halozyme Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 196.95 169.80 83.81 363.82 48.81

Halozyme Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 332.75 503.92 48.81 219.64 143.54
HALO
91GF Score
Halozyme Therapeutics Inc HALO
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of $144 Mil mean?
Halozyme Therapeutics (HALO) has a Total Stockholders Equity of $144 Mil as of Jun. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Halozyme Therapeutics and its competitors.
Is Halozyme Therapeutics' Total Stockholders Equity too high?
Halozyme Therapeutics' current Total Stockholders Equity is $144 Mil. Overall, Halozyme Therapeutics has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Halozyme Therapeutics' Total Stockholders Equity compare to NUVL and KRYS?
Halozyme Therapeutics' Total Stockholders Equity of $144 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Halozyme Therapeutics and its competitors. Halozyme Therapeutics's current Total Stockholders Equity is $144 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Halozyme Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Halozyme Therapeutics (HALO) is currently considered Fairly Valued. The stock's GF Value™ is $98.18, compared to a current price of $106.90 — trading 8.9% above its estimated fair value. The current Total Stockholders Equity is $144 Mil. Halozyme Therapeutics' overall GF Score™ is 91/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Halozyme Therapeutics (HALO), the current Total Stockholders Equity is $144 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Halozyme Therapeutics (HALO) Overvalued in 2026?

Based on GuruFocus' analysis, Halozyme Therapeutics stock appears to be overvalued. The current stock price of $106.90 is trading 8.9% above its estimated GF Value™ of $98.18. GuruFocus considers Halozyme Therapeutics to be Fairly Valued.

Key valuation signals for HALO:

  • Total Stockholders Equity: $144 Mil
  • GF Value™: $98.18 vs. price of $106.90 (8.9% above fair value)
  • GF Score™: 91/100 with 5 warning signs

No single metric tells the full story. See the HALO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Halozyme Therapeutics Business Description

Address 12390 El Camino Real, San Diego, CA, USA, 92130
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
91GF Score

Get the complete analysis for HALO

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$106.90
Price
$98.18
GF Value